We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Five Vascular Diseases Linked to One Genetic Variant

By LabMedica International staff writers
Posted on 09 Aug 2017
Genome-wide association studies have implicated a common genetic variant in chromosome 6p24 in coronary artery disease, as well as four other vascular diseases: migraine headache, cervical artery dissection, fibromuscular dysplasia, and hypertension.

However, it has not been clear how this polymorphism affects the risk for so many diseases. More...
Scientists have now shown how this DNA variant enhances the activity of a gene called endothelin-1, which is known to promote vasoconstriction and hardening of the arteries.

Scientists at Broad Institute of MIT and Harvard University, (Cambridge, MA, USA) and their colleagues examined genetic variants associated with an increased risk for coronary artery disease and myocardial infarction in nearly 200,000 individuals using data from the CARDIOGRAMplusC4D consortium and the 1000 Genomes Project. Specifically, they focused on single-nucleotide polymorphisms (SNPs), variations that affect a single DNA building block.

Their analysis revealed that a SNP called rs9349379, located hundreds of kilobases away, was the strongest risk factor for cardiovascular disease at chromosome 6p24. Additional analysis of UK Biobank data from 112,338 people of European ancestry revealed that a specific form of rs9349379 known as the G allele, which was present in 36% of these individuals, was associated with an increased risk of coronary artery disease.

The investigators then used CRISPR/Cas9 gene editing to delete a small region of DNA at rs9349379 in human pluripotent stem cells and then converted these immature cells into vascular cell to study how rs9349379 regulates the activity of the physically distant endothelin 1 (EDN1) gene. Importantly, analysis of blood samples from 99 healthy individuals showed that the G allele at rs9349379 is associated with higher levels of Big endothelin-1 (ET-1), a precursor protein product of the EDN1 gene. Epigenomic data from human tissue revealed an enhancer signature at rs9349379 exclusively in aorta, suggesting a regulatory function for this SNP in the vasculature. CRISPR-edited stem cell-derived endothelial cells demonstrate rs9349379 regulates expression of EDN1; a gene located 600 kb upstream of Phosphatase And Actin Regulator 1 (PHACTR1).

The authors concluded that overall, these data illustrate the integration of genetic, phenotypic, and epigenetic analysis to identify the biologic mechanism by which a common, non-coding variant can distally regulate a gene and contribute to the pathogenesis of multiple vascular diseases. Sekar Kathiresan, MD, a cardiologist and senior author of the study said, “The main value of our study is the pinpointing of the importance of endothelin-1 and blood vessel constriction to multiple vascular diseases. We also show how to identify a core gene for multiple diseases through genome editing in cells.” The study was published on July 27, 2017, in the journal Cell.

Related Links:
Broad Institute


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.